Engineered Enteric Nervous System-Peri Neural Invasion platform to improve predictive preclinical screens in early-stage colorectal adenocarcinomas

工程肠神经系统-周围神经侵袭平台可改善早期结直肠腺癌的预测性临床前筛查

• 批准号: 10286742
• 负责人: Shreya Raghavan
• 金额: $ 21.97万
• 依托单位: TEXAS ENGINEERING EXPERIMENT STATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10286742
• 关键词: 3-Dimensional; Address; Adjuvant; Adjuvant Chemotherapy; Adjuvant Therapy; Adult; Autologous; Biocompatible Materials; Biological Models; Biomedical Engineering; Clinical; Colon; Colorectal Adenocarcinoma; Colorectal Cancer; Colorectal Neoplasms; Dependence; Development; Engineering; Enteral; Enteric Nervous System; Epithelial Cell Proliferation; Epithelial Cells; Goals; Growth; Histopathologic Grade; Histopathology; In Vitro; Intestines; Malignant - descriptor; Malignant Neoplasms; Modeling; Nerve; Pathologic; Patients; Peripheral Nerves; Plant Roots; Pre-Clinical Model; Process; Prognosis; Publishing; Recruitment Activity; Regulation; Research Project Grants; Resistance; Risk Factors; Role; Sampling; Screening for cancer; System; Technology; Therapeutic; Tissue Engineering; Tumor Tissue; Tumor-Derived; Validation; Work; base; cancer recurrence; cancer stem cell; cellular engineering; chemotherapy; clinical decision-making; clinical practice; clinically significant; colon cancer patients; epithelial stem cell; high throughput screening; improved; innovation; nerve stem cell; new technology; novel; patient response; patient screening; perineural; personalized medicine; pre-clinical; progenitor; programs; relating to nervous system; response; screening; stem cell differentiation; stem cell self renewal; three-dimensional modeling; tool; tumor

PROJECT SUMMARY The objective of this proposal is to engineer and utilize enteric nerve plexi as a tool to improve predictive accuracy of preclinical screens in early stage II-III colorectal cancer (CRC). Peri-neural invasion (PNI) or CRC spread through nerves (especially nerves of the enteric nervous system; ENS) is an independent predictor of poor prognosis. Not only do CRC tumors actively recruit nerves, the ENS-nerves then have the ability to control epithelial cell proliferation and epithelial stem cell differentiation. This is noteworthy because both of these processes can alter CRC dynamics and modulate its response to adjuvant chemotherapy. In current clinical practice, PNI is established by pathological grading, but PNI into the ENS specifically is not considered. We believe that ENS-PNI is an important consideration in clinical decision making, because it could fundamentally alter tumor dynamics and response to adjuvant chemotherapy. Despite clear evidence that PNI is an active contributor to CRC, there are currently no preclinical models of ENS-PNI in CRC which severely limits our ability to investigate and target ENS-PNI. We propose to address this limitation through the development and validation of a novel 3D autologous patient-derived ENS-PNI platform, derived from patient-derived tumor epithelial cells and engineered nerves from adult enteric neural stem cells (ENSCs). We hypothesize that the engineered ENS-PNI platform can predict patient response to adjuvant chemotherapy with high fidelity via ENS regulation of CRC dynamics and cancer stem cell self-renewal. This proposal uniquely leverages the PI’s (Raghavan) published expertise with advanced biomaterial and bioengineered based platforms for engineering the tumor and colon microenvironment, combined with the Co-I’s (Esnaola) clinical expertise and access to patient biospecimen. Through our approach, we will examine the following aims: (1) Develop and validate an in vitro platform of ENS-PNI in CRC; (2) Utilize the engineered ENS-PNI platform to screen patient-derived early stage CRC tumors for adjuvant chemotherapy. We will validate the ENS-PNI platform using histopathology of the patient tumors they are derived from, and compare responses to chemotherapy to clinical responses. This will be the first instance of an in vitro 3D model of ENS-based PNI in CRC. The proposed work fits well into the Exploratory/Developmental Bioengineering Research Grant program, owing to its development of tissue- engineering based technology to improve the capability of preclinical cancer screening. This novel technology will be leveraged to develop a high-throughput amenable screen of stage II/III CRCs with a PNI component, for the purpose of identifying new avenues of targeted adjuvant therapy.

项目概要 该提案的目标是设计和利用肠神经丛作为提高预测能力的工具 早期 II-III 期结直肠癌 (CRC) 神经周围侵犯 (PNI) 或 CRC 临床前筛查的准确性。 通过神经（特别是肠神经系统的神经；ENS）传播是一个独立的预测因子 预后不良 CRC 肿瘤不仅会主动募集神经，而且 ENS 神经也具有控制能力。 上皮细胞增殖和上皮干细胞分化这一点值得注意，因为这两者。 在当前的临床中，这些过程可以改变结直肠癌的动态并调节其对辅助化疗的反应。 实践中，PNI是通过病理分级来建立的，但PNI具体纳入ENS我们并不考虑。 相信 ENS-PNI 是临床决策中的一个重要考虑因素，因为它可以从根本上 尽管有明确的证据表明 PNI 是一种积极的药物，但它会改变肿瘤动力学和对辅助化疗的反应。 作为 CRC 的贡献者，目前尚无 ENS-PNI 在 CRC 中的临床前模型，这严重限制了我们的研究 我们建议通过开发和定位 ENS-PNI 来解决这一限制。 验证源自患者肿瘤的新型 3D 自体患者 ENS-PNI 平台 来自成体肠神经干细胞（ENSC）的上皮细胞和工程神经。 工程化 ENS-PNI 平台可以通过 ENS 高保真度预测患者对辅助化疗的反应 CRC 动态和癌症干细胞自我更新的调节该提案独特地利用了 PI 的作用。 (Raghavan) 发表了先进生物材料和基于生物工程的工程平台的专业知识 肿瘤和结肠微环境，结合 Co-I (Esnaola) 的临床专业知识和获取 通过我们的方法，我们将研究以下目标：(1) 开发并验证一种方法。 (2) 利用工程化的 ENS-PNI 平台进行患者来源的早期筛查 我们将使用组织病理学验证 ENS-PNI 平台。 研究它们来源的患者肿瘤，并将化疗反应与临床反应进行比较。 将是 CRC 中基于 ENS 的 PNI 体外 3D 模型的第一个实例。 探索性/发展性生物工程研究资助计划，归因于其组织- 基于工程的技术可提高临床前癌症筛查的能力。 将利用 PNI 组件开发 II/III 期 CRC 的高通量适应性筛选， 目的是确定靶向辅助治疗的新途径。